The CJEU’s decision in Forsgren has brought greater clarity to the scope of SPC regulation, including whether a substance is an active ingredient as Avi Tolotzis and Penny Gilbert explain in the recent issue of the Life Sciences Intellectual Property Review. 

Please click here for the full article.